Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Expected to Post Quarterly Sales of $10.64 Million

Analysts expect Y-mAbs Therapeutics, Inc. (NASDAQ:YMABGet Rating) to announce $10.64 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Y-mAbs Therapeutics’ earnings, with the highest sales estimate coming in at $11.51 million and the lowest estimate coming in at $9.96 million. Y-mAbs Therapeutics posted sales of $5.38 million during the same quarter last year, which suggests a positive year over year growth rate of 97.8%. The business is expected to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Y-mAbs Therapeutics will report full-year sales of $65.62 million for the current financial year, with estimates ranging from $47.28 million to $117.84 million. For the next year, analysts anticipate that the business will report sales of $85.92 million, with estimates ranging from $63.32 million to $98.68 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that follow Y-mAbs Therapeutics.

Y-mAbs Therapeutics (NASDAQ:YMABGet Rating) last announced its quarterly earnings data on Thursday, February 24th. The company reported ($0.85) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.16). Y-mAbs Therapeutics had a negative return on equity of 25.20% and a negative net margin of 158.40%. During the same period last year, the business earned ($0.49) earnings per share.

Several research firms have weighed in on YMAB. Zacks Investment Research raised Y-mAbs Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 21st. HC Wainwright reduced their price target on Y-mAbs Therapeutics from $68.00 to $63.00 and set a “buy” rating for the company in a research note on Monday, February 28th. Guggenheim started coverage on Y-mAbs Therapeutics in a research note on Thursday, February 3rd. They issued a “buy” rating and a $22.00 price target for the company. Finally, JPMorgan Chase & Co. cut their target price on Y-mAbs Therapeutics from $30.00 to $27.00 and set a “neutral” rating for the company in a research report on Monday, January 3rd. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $37.80.

NASDAQ:YMAB opened at $12.82 on Tuesday. The business’s 50-day simple moving average is $10.07 and its 200-day simple moving average is $15.95. Y-mAbs Therapeutics has a fifty-two week low of $6.50 and a fifty-two week high of $39.82. The stock has a market capitalization of $560.41 million, a PE ratio of -9.98 and a beta of 1.36.

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 8,000 shares of the stock in a transaction that occurred on Tuesday, January 18th. The stock was sold at an average price of $11.54, for a total value of $92,320.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Bo Kruse sold 4,000 shares of the stock in a transaction that occurred on Monday, January 24th. The stock was sold at an average price of $9.84, for a total value of $39,360.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 419,189 shares of company stock worth $3,905,095. 27.28% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. Point72 Hong Kong Ltd bought a new position in shares of Y-mAbs Therapeutics in the third quarter valued at approximately $28,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Y-mAbs Therapeutics during the third quarter valued at approximately $49,000. Advisor Group Holdings Inc. purchased a new stake in shares of Y-mAbs Therapeutics during the fourth quarter valued at approximately $67,000. BNP Paribas Arbitrage SA increased its position in shares of Y-mAbs Therapeutics by 322.1% during the third quarter. BNP Paribas Arbitrage SA now owns 6,449 shares of the company’s stock valued at $184,000 after acquiring an additional 4,921 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Y-mAbs Therapeutics during the fourth quarter valued at approximately $204,000. Institutional investors own 67.21% of the company’s stock.

Y-mAbs Therapeutics Company Profile (Get Rating)

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.

Featured Stories

Get a free copy of the Zacks research report on Y-mAbs Therapeutics (YMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.